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Abstract
Background: A wide variety of animal models have been used to study human breast cancer.
Murine, feline and canine mammary tumor cell lines have been studied for several decades and have
been shown to have numerous aspects in common with human breast cancer. It is clear that new
comparative approaches to study cancer etiology are likely to be productive.
Results: A continuous line of breast carcinoma cells (WalBC) was established from a primary
breast cancer that spontaneously arose in a female tammar wallaby (Macropus eugenii). The primary
tumor was 1.5 cm3 and although large, did not appear to invade the stroma and lacked vimentin
expression. The WalBC cell line was cultured from the primary tumor and passaged for 22 months.
WalBC cells displayed an epithelial morphology when grown on plastic, were not EGF responsive,
stained strongly for cyto-keratin and negatively for vimentin. WalBC cells were shown to be non-
invasive within a Matrigel invasion assay and failed to produce tumors following transplantation into
nude mice. Gene expression profiling of WalBC cells was performed using a cDNA microarray of
nearly 10,000 mammary gland cDNA clones and compared to normal primary mammary cells and
profiles of human breast cancer. Seventy-six genes were down-regulated and sixty-six genes were
up-regulated in WalBC cells when compared to primary mammary cells. WalBC cells exhibited
expression of known markers of basal invasive human breast cancers as well as increased KRT17,
KRT 14 and KRT 19, DSP, s100A4, NDRG-1, ANXA1, TK1 and AQP3 gene expression and
decreased gene expression of TIMP3, VIM and TAGLN. New targets for breast cancer treatment
were identified such as ZONAB, PACSIN3, MRP8 and SUMO1 which have human homologues.
Conclusion: This study demonstrates how novel models of breast cancer can provide new
fundamental clues regarding cancer etiology which may lead to new human treatments and
therapies.
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Background
Breast cancer is the leading cause of mortality and mor-
bidity of women in many countries and is truly a multi-
disiplinary problem. New ways are currently being sort to
develop a new focus and new perspectives. One of these
methods involves the study of alternative models of breast
cancer for use in comparative oncology. Comparative
oncology uses breast cancer models proffered by other
species in an attempt to gather more information about
breast cancer which may give rise to new human therapeu-
tic targets and interventions.
Murine, feline and canine breast cancer models have been
studied extensively showing numerous commonalities
with human breast cancer [1,2], [57]. Carcinomas of the
mammary gland are common among carnivorous ani-
mals and although rare in herbivores, have been docu-
mented in such animals as the horse [3]. Mammary
neoplasms in marsupials have not been reported to date,
and interestingly, marsupials spend a relatively long
period in a state of lactation.
The morphology of the wallaby mammary gland is similar
to other mammals but the lactation strategy adapted by
marsupials is different to eutherians. The gland undergoes
lobular alveolar development during a short period of
pregnancy (26.5 days) and the mother gives birth to an
altricial young [4]. During a relatively long lactation the
mother progressively changes it's milk composition to
regulate the considerable growth and development of the
young [5-8]. The mammary gland grows considerably
during lactation [4] and, at the end of lactation the mam-
mary gland undergoes involution and returns to a virgin-
like state [4].
The ability to establish primary cultures of tumor cells is
an important prerequisite in cancer research, allowing the
study of carcinogenesis, prognostic factors and therapeu-
tic agents [9]. In this report, a mammary carcinoma in a
tammar wallaby was examined by histopathological tech-
niques and a breast cancer cell line was established
(WalBC). Transcriptional profiling using a custom tam-
mar wallaby microarray was performed on the WalBC cell
line identifying a gene expression profile consistent with
human basal-like breast cancer. Moreover, in addition to
the known markers for basal-like breast cancer, the WalBC
cell line expressed a number of genes with homologues in
the human genome, but have not previously been associ-
ated with breast cancer. Further study of these genes
within human models of breast cancer may provide new
clues in the development and progression of breast cancer
which may in turn lead to new treatments and therapies.
Materials and methods
Animals, tumor detection and surgery
Tammar wallabies used in this study were part of a captive
breeding colony maintained in an open enclosure at The
University of Melbourne Macropod Research Facility
(Melbourne, Victoria), with stock originally from Kanga-
roo Island, South Australia. Care and treatment of animals
conformed to the National Health and Medical Research
Council of Australia and were approved by the Victorian
Department of Sustainability and Environment Ethics
Committee. The animal presenting with a mammary
lesion was part of the breeding colony for two years (Feb-
ruary 2002 – February 2004) and was checked monthly
during this time for signs of mating and presence of pouch
young. The animal did not reproduce in this time but pre-
sented with a mammary lesion. The animal was subse-
quently monitored weekly for three weeks then
euthanized. The lesion was measured, excised and either
immediately frozen for future RNA extraction, placed in
Hanks' Balanced Salt Solution (HBSS) (Sigma Aldridge,
Sydney, Australia) at 4°C in preparation for isolation of
mammary cells or fixed in formalin for histology. The tis-
sue from the mammary gland was divided into two por-
tions, one comprising the main body of the mammary
lesion and the other comprising normal mammary tissue.
Mammary gland tissue was also collected from a wallaby
of comparable age and reproductive status for preparation
of mammary epithelial cells.
Preparation of WalBC cell line and wallaby primary 
mammary epithelial cells
Tissue was immediately transferred to 1× Hanks' Balanced
Salt Solution (HBSS) (Gibco, USA) with 20 µL/mL peni-
cillin/streptomycin (Gibco, USA) and 5 µg/mL Fungizone
(Gibco, USA) on ice and transported back to the labora-
tory for enzymatic digestion to harvest mammary epithe-
lial cells.
Tissue was dissected free from fat, weighed, sliced finely
and digested with 1 µg/mL Collagenase Class2 (Worthing-
ton UK), 10 mL/L penicillin/streptomycin (Gibco, USA),
10 mL/L fungizone (Gibco, USA), 0.35% Bovine Serum
Albumin (Sigma) and a final concentration of 0.5 mM
glucose. 10 g of tissue per 100 mL of media was digested
shaking at 200 rpm at 37°C for 4 h. Cells were harvested
by filtration through 150 µm nylon mesh using a Nalgene
filter unit. The suspension was centrifuged at 80 g for 5
min and pellets were washed twice with HBSS containing
0.02 mg/mL DNase 1 (Invitrogen) and 1 mg/mL Trypsin
Inhibitor (Sigma). Cells were again suspended in wash
media, then filtered through 53 µM nylon mesh, re-centri-
fuged and finally resuspended in FCS/10%DMSO
(DMSO-Sigma, Sydney, Australia), and frozen at a density
of ~2 × 107 cells/mL.Molecular Cancer 2008, 7:1 http://www.molecular-cancer.com/content/7/1/1
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WalBC cells and wallaby primary mammary cells were
cultured in either 25 or 80 cm2 culture flasks in 10 mL or
20 mL respectively of M199/Hams/Hepes media with 1
µg/mL cortisol, 10 ng/mL EGF, 1 µg/mL insulin supple-
mented with 10% fetal bovine serum. WalBC cells were
passaged (more than 20 times) when confluent by scrap-
ing and use of versine solution in phosphate buffered
saline (PBS) (Sigma-Aldrich, Sydney, Australia). Passag-
ing of cells with 0.1% trypsin-versine in phosphate buff-
ered saline (PBS) (Sigma-Aldrich, Sydney, Australia) for 2
minutes at 37°C disrupted cellular aggregates but cells
failed to retain viability following this treatment.
Histology
Tissue was fixed in 10% formalin for 24 h. Samples were
processed (Citadel; Shandon Scientific Ltd., Cheshire,
England), and embedded in paraffin using routine proce-
dures. Paraffin-embedded sections of 5 µm thickness were
cut, mounted on 3-aminopropyltriethoxysilane-coated
slides and submerged in histolene to remove the paraffin.
After rehydration, sections were stained with haematoxy-
lin and eosin. Finally, sections were coverslipped and
examined using an Olympus BX40 microscope and
Coolscope digital microscope (Nikon) for light micros-
copy.
Immunohistochemistry
Paraffin-embedded sections of 5 µm thickness were cut
and mounted on 3-aminopropyltriethoxysilane-coated
slides and submerged in histolene to remove the paraffin.
After rehydration, tissue peroxidases were blocked for 30
min with a 1% hydrogen peroxide solution and washed
with 1× PBS. For detection of Vimentin, sections under-
went treatment with sodium citrate buffer. Sections were
then blocked for 60 minutes with 10% goat serum
(Sigma)/1% BSA/PBS prior to addition of Vimentin anti-
body (V9, 1:800; Dako, Australia) at 4°C overnight. An
HRP-conjugated goat anti-mouse secondary antibody
(1:250 dilution; Dako, Australia) was then applied for 1
hour to allow a brown precipitate to develop using AEC
(Dako, Australia). Finally, sections were counterstained
with eosin, dehydrated, coverslipped and examined using
a Coolscope digital microscope (Nikon) for light micros-
copy.
Proliferation assay and cell morphology
WalBC or wallaby MEC's cells were plated (2000 cells/
well) in 96 well plate formats with growth media contain-
ing either insulin (I; 1 µg/ml), cortisol (F; 1 µg/ml) and
prolactin (P; 1 µg/ml) or I, F, Epidermal growth factor
(EGF; 10 ng/ml). Cells were grown for a further 10 days
before being fixed and stained with Sulforhadamine B as
previously described [10]. Each time point was performed
in quadruplicate. Cells were visualized by phase contrast
microscopy using an Olympus BX40 microscope and pho-
tographed using a DigitalSight DSL1 (Nikon) camera.
Matrigel outgrowth assay
Matrigel outgrowth assays were performed in 48 well
plates as previously described (Price and Thompson,
1999). Cells (2 × 104) were dispersed in 75 µL of undi-
luted Matrigel (approx.10 mg/mL) and then overlaid onto
100 µL of polymerized undiluted Matrigel. Once the top
layer had polymerized the cultures were incubated in
MEM/10%FBS media for up to 10 days and photographed
at 20 × magnification by phase contrast microscopy using
an Olympus BX40 microscope and photographed using a
DigitalSight DSL1 (Nikon) camera.
In vivo studies
Mice (3–4 week old intact female Balb/C nu/nu) were pur-
chased from Australian Resource Center (Perth, Aus-
tralia), housed in individually ventilated cages under
filtered air (Techniplast, Milan, Italy) and acclimatized for
one week prior to manipulation. Anesthesia was achieved
by i.p injection of ketamine/xylazine (Provet; Australia;
40  µg/g mouse and 16 µg/g mouse, respectively). The
mice were allowed to recover from the anesthesia before
being returned to their cages and monitored daily. Animal
studies were conducted with ethical approval of the St.
Vincent's Hospital Animal Ethics Committee (Melbourne,
Australia), and in accordance with the Australian National
Health and Medical Research Council's Guidelines for the
Care and Use of Laboratory Animals.
Mammary fat pad inoculation of WalBC cells
WalBC cells were harvested from near confluent condi-
tions, aspirated into cell suspension (cell aggregates and
single cells were present), washed thrice and resuspended
in PBS before inoculation. Two groups of 8 mice received
mammary fat pad inoculation of WalBC cells (5 × 105
cells/15 µL) as described by Price et al [11]. Tumor growth
was assessed by monitoring the fat pad for palpable
tumors at weekly intervals. Mice were sacrificed after 6
months.
Immunocytochemistry
WalBC cells grown on plastic were fixed in 4% parafor-
maldehyde (30 min) and washed three times in PBS. Cells
were permeabilized with 0.1% Triton X/PBS (5–10 min)
and washed thrice with PBS before blocking in 1% BSA for
30 min. Either Vimentin9 (Dako; 1/800) or Rabbit anti-
cytokeratin (Bectin Dickinson1/400) antibody was added
in blocking buffer and incubated overnight at 4°C. Cells
were then washed five times in PBS to remove non-spe-
cific binding of primary antibody. Cells were then incu-
bated in goat anti-mouse (FITC) (DAKO; 1/400) or goat
anti-rabbit (FITC) (DAKO; 1/400) in blocking buffer for 1
hour and washed thrice with PBS. Nuclei were visualizedMolecular Cancer 2008, 7:1 http://www.molecular-cancer.com/content/7/1/1
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using Propidium Iodide (Invitrogen). Images were visual-
ized for fluorescence using an Olympus BX40 microscope
and photographed using a DigitalSight DSL1 (Nikon)
camera.
RNA preparation for gene expression by microarray 
analysis
WalBC cells, primary mammary cells cultured from the
same animal and primary wallaby mammary cells cul-
tured from a virgin animal of similar age were scraped
from tissue culture dishes using Tripure (Roche). Total
RNA was isolated from the aqueous phase and further
purified using the Qiagen RNeasy miniprep kit (Sydney
Australia) following the manufacturer's instructions.
RNA Amplification was done in 3 parts similarly to the
Eberwine protocol [12]. First strand synthesis utilized
MMLV RNase H- (Promega M3681) and second strand
synthesis was done with DNA Polymerase 1 (Promega,
M2501). Lastly in vitro transcription was performed with
the T7 Megascript Kit (Ambion 1334). The resulting
amplified RNA was then further purified using the QIA-
GEN RNeasy miniprep kit.
The amplified RNA from each treatment group was
labeled using amino allyl reverse transcription followed
by Cy3 and Cy5 coupling. Samples of amplified RNA (10
mg) were reverse transcribed using 5 µg random hexamers
(Geneworks), MMLV reverse transcriptase (Promega),
RNAse H (Invitrogen) and 1× buffer at 42°C for 2.5
hours. The reaction mix was hydrolyzed by incubation at
65°C for 15 minutes in the presence of 55 mM NaOH, 55
mM EDTA followed by a subsequent addition of acetic
acid to 50 mM. The cDNA was then adsorbed to a Qiagen
QIAquick PCR Purification column. Coupling of either
Cy3 or Cy5 dye was performed on the column by incubat-
ing the adsorbed cDNA with the appropriate dye in 0.1 M
sodium bicarbonate pH 9.0 for 1 hour at room tempera-
ture in darkness. Each labeled cDNA was eluted in 80 µl
of water and was then combined with its comparing sam-
ple during further purification on a second Qiagen
QIAquick PCR Purification column. The joint Cy3 and
Cy5 labeled probe in a final concentration of 0.4 mg/ml
yeast tRNA, 1 mg/ml human Cot 1 DNA, 0.2 mg/mL Poly
dA50, 1.25 × Denharts, 3.2 × SSC and 50% formamide was
heated to 100°C for 3 minutes. SDS, to 0.1%, was added
immediately after heating and just prior to application.
Probes were hybridized to custom made tammar wallaby
EST microarray slides overnight at 42°C in a HyPro20
(Integrated Science) humidified chamber. The slides were
printed with 10,000 EST's from tammar mammary gland
cDNA libraries generated from tissue collected across the
lactation cycle (Lefevre, manuscript in preparation).
The tammar EST database was derived from several cDNA
libraries comprising day 23 pregnant (n = 4), lactating at
day 130 (n = 4), lactating at day 260 (n = 1), lactating at
day 130 subtracted for all the major milk protein genes (n
= 2), non-lactating (n = 2) and a normalized library (com-
bined RNA from day 26 pregnant, lactating at day 55, day
87, day 130, day 180, day 220, day 260 and involuting at
day 5).
Microarray's were washed in 0.5× SSC, 0.01% SDS for 1
minute, 0.5× SSC for 3 minutes then 0.006× SSC for 3
minutes at room temperature in the dark. Slides were cen-
trifuged dry at 130 g for 5 minutes then scanned with a
VersArray Scanner (BioRad). Images were analyzed using
Versarray Software (Biorad).
Analysis of gene expression data
Gene expression data was normalized using the single
channel normalization method in the Limma package of
Bioconductor [13]. These normalized expression values
were analyzed using a two-stage process [14]where all the
expression values are considered simultaneously. The first
stage involves fitting a linear mixed model [15]of the form
Madj = µ + Treatment + Probe + Treatment.Probe + ε
where Madj is the adjusted (loess-normalized) log inten-
sity ratio for a probe on the cDNA array, Treatment is the
fixed effect of the treatment (tumor cells, non-tumor cells,
or virgin), Probe is the random effect of the probe on
expression levels, regardless of the treatment, and Treat-
ment.Probe is the random effect of a particular probe
within a particular treatment, the effect of interest. Typi-
cally, the distribution of these random Treatment.Probe
effects show a mixture of two distributions, one with
small variance (non-differentially expressed genes, non-
DE) and one with large variance (differentially expressed,
DE). So the second stage involved fitting a two-compo-
nent mixture model (DE vs non-DE) to these effects [16],
and this will return the (posterior) probability that a par-
ticular gene is DE, given its Treatment.Probe effect, with a
probability in excess of 0.5 indicating a gene is more likely
DE, for that particular treatment. However, a stringent
threshold has been used requiring a posterior probability
in excess of 0.999 before a gene was classified as being DE,
in order to reduce the false positive rate. The statistical
package R was use for this two-stage process.
Statistical analysis
To determine the significance of EGF response within
each cell type a paired students t-test was performed on
quadruplicate samples at day 10. For Matrigel outgrowth,
20 outgrowths were measured for each cell type at day 4
in a given area and averaged. Unpaired t-test was used toMolecular Cancer 2008, 7:1 http://www.molecular-cancer.com/content/7/1/1
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determine significance differences in the length of out-
growths between the two cell types.
Results
Pathology and immunoreactivity of a wallaby primary 
tumor
A 1.5 cm3 mammary lesion was detected in a female, non-
pregnant, non-lactating tammar wallaby (Fig. 1). The
female was not less than two years of age, although her
true age was not determined as she was captured from the
wild and held in a captive colony for two years prior to
tumor presentation. Examination by histological tech-
niques showed primary tumor cells were present within
the gland arranged in solid masses which appeared to dis-
play a pushing margin that invaded the stroma (Fig. 2A).
Anti-vimentin immunostaining revealed positive vimen-
tin immunoreactivity of the stroma and negative immu-
noreactivity of the tumor cells (Fig. 2B).
Characterization of the WalBC cell line: Morphology, 
immunoreactivity and growth/invasive potential
The WalBC cell line was grown from a mixture of cells
containing both normal mammary stromal/epithelial
cells and primary cancer cells (Fig. 3A). The WalBC cell
line formed a monolayer comprising a homogeneous cell
population which exhibited epithelial morphology and
strong cell-cell interactions. Once established, the WalBC
cell line was passaged for 2 years, cells maintained a
cuboidal morphology and proliferated to islands of con-
fluent cells. Single cells did not survive in the absence of
cell contact and passaging of cells required the presence of
large cellular aggregates which attached to the tissue cul-
ture treated plastic before initiating proliferation. Use of
trypsin for passaging was unsuccessful due to the break
down of cellular aggregates. The morphology of wallaby
primary cells and WalBC cells grown in culture was mark-
edly different with WalBC cells appearing smaller and
exhibiting strong cell-cell contact (Fig. 3B, C).
Immunostaining with anti-cytokeratin of WalBC cells
grown in culture showed 90% of cells exhibited strong
cytokeratin immunoreactivity which localized to the cyto-
plamic region of positive cells (Fig. 3D). A small popula-
tion of cells showed weaker cytokeratin
immunoreactivity, however all cells appeared to show
some degree of immunoreactivity.
The proliferation rate of the WalBC cell line was compared
to primary wallaby epithelial cells (MEC's) in the presence
of insulin (I), cortisol (F) and prolactin (P) or I, F and epi-
dermal growth factor (EGF). Wallaby MEC's exhibited a
higher proliferation rate compared to WalBC (Fig. 4).
Wallaby MEC's also showed an increase in proliferation in
the presence of EGF compared to growth in the presence
of prolactin (P < 0.01) while the WalBC cell line failed to
respond to EGF treatment.
The invasive potential of the WalBC cell line was exam-
ined by Matrigel invasion assay. This assay has previously
associated stellate Matrigel morphology with invasiveness
in human breast cancer cell lines [11,17]. The WalBC cell
line failed to exhibit stellate growth but grew mammary-
like structures that resemble ducts and lobules (Fig. 5).
These structures also mimicked the morphology exhibited
by the in situ primary lesion which showed masses of
tumor cells surrounded by stromal cells. Matrigel mor-
phology analysis was also performed on a known human
invasive breast cell line, MDA-MB-231 which demon-
strated stellate outgrowth as expected. Comparative quan-
titative analysis was performed to determine the average
length of outgrowth between WalBC and MDA-MB-312
cells. The average outgrowth for WalBC cells in Matrigel
was found to be 145 µm (standard deviation of the mean
= 72.147) and MDA-MB-231 cells showed an average out-
growth of 50.75 µm (standard deviation of the mean =
20.601). The difference between the length of outgrowths
between the two cell types was determined to be highly
significant (P < 0.0001). An in vivo model of tumor
growth in nude mice was used to study the degree of
tumorgenicity of the WalBC cell line. WalBC cells were
tested on two separate occasions using two groups of eight
mice and a different WalBC passage numbers and on both
occasions WalBC cells failed to generate palpable tumors
(data not shown).
In situ wallaby breast tumor Figure 1
In situ wallaby breast tumor. A 1.5 cm3 breast lesion (white 
arrow) was identified within the left posterior mammary 
gland of a non-lactating mature female tammar wallaby. Mam-
mary glands are indicated by white arrowheads and teats are 
indicated by black arrows. Skin has been cut away and pulled 
back to expose the area.Molecular Cancer 2008, 7:1 http://www.molecular-cancer.com/content/7/1/1
Page 6 of 14
(page number not for citation purposes)
WalBC gene expression profile
The gene expression profile of the WalBC cells was com-
pared to primary mammary epithelial cells (MEC's) from
the same animal and virgin mammary epithelial cells
grown from a different animal using a microarray with
10,000 tammar mammary ESTs [18]. Genes were consid-
ered differentially expressed if there was a 2-fold or more
increase or decrease of intensity between WalBC and both
normal MEC's from the same animal and virgin MEC's
from a different animal, with a posterior probability of
>0.999. Gene expression profiles revealed a large number
of differentially expressed genes were associated with car-
cinogenesis (Table 1 and 2). The highest up-regulated
gene in the WalBC cell line was cytokeratin 17 while
vimentin was down regulated. Notably WalBC cells
showed up regulated expression of DSP, s100A4, ANXA1,
NDRG-1, TK1 and down regulation of genes such as tissue
inhibitor of TIMP-3 and TAGLN. The overall expression
profile revealed a pattern of gene expression consistent
with basal-type breast cancer. A number of EST's were also
identified that have not been previously associated with
breast cancer. These included CAP43, SALL1, ZONAB,
SUMO-1 and MRP8 and a number of hypothetical pro-
teins with homologues within the human genome.
Discussion
A wide variety of animal models have been used to study
human breast cancer [19]. For example, murine, feline
Histological analyses of normal tammar wallaby mammary gland and primary breast cancer from the same animal Figure 2
Histological analyses of normal tammar wallaby mammary gland and primary breast cancer from the same animal. (A) H & E 
staining of wallaby carcinoma within breast tissue showing solid tumor architecture with an invading margin. Basophilic tumor 
cell nests are stained blue and are indicated by the arrow. (B) Vimentin staining shows cancer cells are vimentin (V9) negative, 
while vimentin expression can be identified (brown) within the stromal tissue. (C) H &E staining of normal tammar wallaby 
mammary gland showing alveolar structures (arrowed) and (D) stroma staining of vimentin (V9) (brown). Scale bars are shown.Molecular Cancer 2008, 7:1 http://www.molecular-cancer.com/content/7/1/1
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and canine mammary tumor cell lines have been studied
for several decades and have shown to have numerous
aspects in common with human breast cancer [1,2,20].
We present here the first reported discovery of a primary
breast lesion in a marsupial and the subsequent establish-
ment and characterization of the first wallaby breast can-
cer cell line for comparative analysis of breast cancer. The
primary lesion lacked vimentin expression and the cell
line was shown to be cytokeratin positive which is consist-
ent with basal type invasive carcinoma.
In all species studied extensively so far, the ability of inva-
sive tumor cells to interact specifically with, and invade,
the extracellular matrix (ECM) has been linked to breast
cancer progression [21-23]. From these studies it can be
concluded that malignant progression is a stepwise proc-
ess and tumor growth occurs after a series of molecular
events that parallel morphological changes indicative of
cell transformation. It has been well established that the
invasive capability of a breast cancer cell line can be accu-
rately predicted by performance in an in vitro three dimen-
sional Matrigel outgrowth assay [17,24-29]. When placed
on reconstituted basement membrane (Matrigel) breast
cancer cell lines with the potential to metastasize have
been shown to demonstrate stellate branching morphol-
ogy and invade the matrix, while non-invasive cell lines
fail to grow or develop into spherical bunches of cells
without invading the matrix [17]. This in vitro phenome-
non is thought to mimic the in vivo interaction of tumor
cells with the surrounding matrix and demonstrates the
ability of the tumor cell to degrade the basement mem-
brane, which encapsulates the primary tumor, and allows
individual cells to migrate from the initial tumor mass
into the breast stroma and eventually establish within the
lymph gland which aids dispersal to other organs of the
body. In stark contrast, normal mammary epithelial cells
form polar acini, similar to alveoli breast structures when
plated on a layer of Matrigel [30-32]. The WalBC cells
appeared to exhibit a non-invasive phenotype, however
the growth pattern in Matrigel did not resemble the spher-
ical bunches of cells exhibited by other non-invasive cell
lines [17] but appeared to exhibit a normal branching and
lobular development. This difference in morphology
could be due to difference in cellular signaling via the
components within Matrigel. It has been shown that
mammary epithelial cells exhibit species-specific cell
interaction with their surrounding extracellular matrix.
Fur seal (Arctocephalus pusillus pusillus) mammary epithe-
lial cells only form acinar structures capable of expressing
milk protein genes when grown on their own matrix and
display invasive morphology when grown on Matrigel
[33]. A similar effect is also seen with primary wallaby
mammary cells, which exhibit stellate outgrowth on
Matrigel and only form acinar structures capable of pro-
ducing milk when grown on their own matrix (Mailer and
Cell morphology in in vitro culture Figure 3
Cell morphology in in vitro culture. (A) Initial culture of mam-
mary tumor showed two cell types growing within the flask. 
Continued culture allowed primary mammary cells (indicted 
by p) to die off leaving only the tumor cells (indicated by t). 
(B) Primary mammary wallaby cells and (C) established wal-
laby breast cancer cell line (WalBC) after passaging for 22 
months grown on tissue culture treated plastic. (D) WalBC 
cells exhibited positive cytoplasmic staining for cytokeratin 
(green). Cell nuclei are stained red using propidium iodide. 
Scale bars are shown.Molecular Cancer 2008, 7:1 http://www.molecular-cancer.com/content/7/1/1
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Nicholas unpublished data). These observations suggest
Matrigel may not be an adequate substrate to test the inva-
sive potential of wallaby breast cancer cell lines and a wal-
laby derived ECM would be better suited to use with these
cells as it has the potential to more closely mimic the in
vivo environment. Similarly, the failure of WalBC cell to
establish tumorgenicity using the nude mice xenograph
model may also be subject to the same species specific
restraints.
Epidermal growth factor (EGF), a polypeptide found in
human and animal blood and secretions, is an important
mitogen in breast epithelial cells. EGF has been found to
stimulate a variety of tissues including normal rodent
breast tissue and rodent breast cancer [34] and human
breast epithelial cells in culture [35] and fibridomas [36].
In MCF-7 cells as little as 0.01 ng/ml of EGF stimulates cell
growth and 10 ng/ml was maximal, however, EGF shows
no effect on another human breast cancer cell line, MDA-
MB-231. [37]. Similarly, primary wallaby epithelial cells
shows a growth response to EGF while the WalBC cell line
was not EGF responsive as these maximal doses. It is sug-
gested that some breast cancers retain EGF sensitivity
observed with nonmalignant mammary cells, while it is
lost in others. The slow growth rate observed for the
WalBC cell line compared with the primary cells may indi-
cate that this cell line requires other hormones/factors for
maximal growth.
Newly emerging data about the genomes of other species
such as the marsupial and the availability of 15,000 breast
specific wallaby cDNA's expressed at all stages during the
lactation cycle, and a 10, 000 ESTs array offers the rare
opportunity to profile the WalBC cell line for gene expres-
Comparison of invasive potential of wallaby and human  breast cancer cell lines Figure 5
Comparison of invasive potential of wallaby and human 
breast cancer cell lines. The wallaby breast cancer cell line, 
WalBC and human breast cancer cell line, MDA-MB-231 
were grown within Matrigel (4 days). (A, B) WalBC cells 
exhibit development of mammary-like structures suggestive 
of a non-invasive phenotype and (C) MDA-MB-231 cells 
exhibit stellate outgrowth suggestive of an invasive pheno-
type.
Comparative analysis of proliferation rates between WalBC  and wallaby MEC's Figure 4
Comparative analysis of proliferation rates between WalBC 
and wallaby MEC's. Cells were grown for 10 days in the pres-
ence of insulin (I), cortisol (F) and prolactin (P) or I, P and 
epidermal growth factor, EGF (E). Wal MEC's responded to 
the presence of EGF (P = 0.0041, 95% confidence interval, t 
= 8.0113, df = 3).Molecular Cancer 2008, 7:1 http://www.molecular-cancer.com/content/7/1/1
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Table 1: Up-regulated genes in WalBC cell line.
Gene +ve Fold change1 c/w MEC's +ve Fold change1 c/w virgin MEC's Wallaby array Human Unigene
2 KRT17 30.073 5.751 SGT20f3_B03 Hs.2785
2 KRT14 26.983 3.388 SGT20m2_B01 Hs.355214
unknown 16.757 2.863 SGT20s4_B07
2 DSP 15.967 4.621 SGT20w1_H09 Hs.349499
2 S100A14 13.558 4.540 SGT20j6_D06 Hs.288998
2 FABP5 11.835 4.202 SGT20k1_B09 Hs.414321
KERV-1 11.131 6.870 SGT20r1_G05
PIGPC1 8.865 4.520 SGT20u3_F08 Hs.303125
2KRT17 8.671 4.912 SGT20t2_C06 Hs.2785
DZ-HRGP 8.033 2.635 SGT20h1_E03 Hs.330537
SNK 7.208 4.010 SGT20r1_E01 Hs.375912
2AQP3 5.941 8.356 SGT20l2_D09
2 NDRG1 5.596 3.378 SGT20c1_B05 Hs.75789
2TK2 5.430 3.310 SGT20u4_B02 Hs.105097
SALL1 5.315 2.024 SGT20h1_C08
2 EIF5A 5.296 3.989 SGT20i3_B10 Hs.381006
TP73L 4.920 3.483 SGT20v4_H01
2ANXA1 4.822 2.234 SGT20n1_D06 Hs.78225
MET 4.790 2.524 SGT20h2_E01
2 MeCP2 4.634 3.279 SGT20f1_G03 Hs.25674
HGNC 4.483 2.218 SGT20o1_G06 Hs.331195
2 PTPN12 4.477 2.903 SGT20i4_F05 Hs.62
2 MeCP2 4.261 3.164 SGT20v3_G09 Hs.25674
2CST6 4.189 2.143 SGT20n1_F03 Hs.83393
UCH-L3 4.184 2.167 SGT20m2_G11 Hs.77917
HERV-K pol 4.144 3.806 SGT20j6_F04
Hs3st3b 4.067 2.765 SGT20l2_F04 Hs.8040
AP1M2 4.021 2.062 SGT20h4_C03 Hs.18894
W86 retroposon 3.890 2.403 SGT20k3_A02
Envelope protein 3.859 2.167 SGT20o3_C12
STK24-like 3.764 2.017 SGT20j6_C11 Hs.168913
MRP8 3.530 2.085 SGT20w4_B01 Hs.335891
BDP1 3.476 2.914 SGT20q4_C12 Hs.380461
RP1-119E23 on chromosome Xq25-27.1 3.386 2.290 SGT20l1_B06
2 ANXA1 3.254 3.022 SGT20k2_A08 Hs.78225
MYH7 3.210 2.197 SGT20u4_B10
RIKEN cDNA 0610009O03 gene 3.138 2.511 SGT20k3_E06 Hs.157145
Hypothetical protein XP_148915 3.110 2.333 SGT20h4_C11 Hs.385695
2 Cap43 3.102 2.243 SGT20r4_B01 Hs.381559
2HSPA1A 2.998 2.406 SGT20d4_F03 Hs.80288
2CK19 2.977 2.120 SGT20o4_G10 Hs.182265
MYO10 2.737 2.110 SGT20f3_B11 Hs.61638
Sumo-1 2.728 2.646 SGT20v3_B08 Hs.81424
2 NPKC-ZETA 2.701 3.062 SGT20k4_H11 Hs.78793
ZONAB 2.639 2.321 SGT20c5_F02 Hs.198726
14-3-3 zeta 2.632 2.117 SGT20n4_D05 Hs.75103
BAC clone RP11-391A7 2.721 2.307 SGT20k3_E11
Hypothetical protein DKFZp434H2035.1 2.589 2.477 SGT20i6_H04 Hs.381781
ATDC 2.547 2.148 SGT20q3_F11 Hs.82237
RP11-554F11 on chromosome 10 2.528 2.010 SGT20d5_G01
2 HSPB1 2.516 2.761 SGT20k3_G03 Hs.385457
SPC18 2.466 3.827 SGT20u4_A12 Hs.68644
Replicase 2.465 2.009 SGT20i5_D11
gp1 2.455 2.378 SGT20i5_B12
2KRT14 2.379 2.583 SGT20d5_B06 Hs.355214
ITMCII-3b 2.370 2.042 SGT20e2_F01 Hs.433982
Hypothetical protein 2.361 2.762 SGT20l2_F09
LAT 2.354 2.085 SGT20q3_F05
protein for MGC:33586 2.279 2.855 SGT20i3_H10 Hs.348516Molecular Cancer 2008, 7:1 http://www.molecular-cancer.com/content/7/1/1
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SBDS 2.226 2.778 SGT20e2_G04 Hs.110445
2AHA1 2.179 2.169 SGT20s4_B04 Hs.204041
3 BAC RP11-641D5 2.172 2.652 SGT20i6_A03
DKFZp667G2110 2.164 2.725 SGT20q4_B10 Hs.406105
UBE2C 2.146 2.374 SGT20r5_F02 Hs.26213
SLC3A 2.091 2.120 SGT20o5_D01 Hs.79748
2CLDN4 2.030 3.757 SGT20f4_E07 Hs.5372
PACSIN3 2.008 2.504 SGT20t1_F02 Hs.334639
1P > 0.999 and > 2 fold
2 Previously associated with breast cancer
Table 1: Up-regulated genes in WalBC cell line. (Continued)
Table 2: Down-regulated genes in WalBC cell line.
Gene -ve Fold change1 c/w MEC's -ve Fold change1 c/w virgin MEC's Wallaby array Human Unigene
2TAGLN 28.315 12.585 SGT20p3_D11 Hs.433399
GSTP1 24.654 10.312 SGT20b1_E11 Hs.226795
CYR61 23.276 20.831 SGT20l1_B02 Hs.8867
PCPE 21.766 12.276 SGT20v3_A09 Hs.202097
CLU 14.308 19.773 SGT20k1_D12 Hs.433909
OPG 14.182 2.245 SGT20h4_G04 Hs.81791
LTBP-1 12.281 3.654 SGT20u5_B04 Hs.241257
COL11A2 12.076 13.887 SGT20s4_B10 Hs.179573
ZP3 11.225 14.406 SGT20c5_D09
STEAP1 10.141 3.472 SGT20h4_D01 Hs.61635
SORBS2 9.922 5.057 SGT20p1_G06 Hs.379795
FCRN 9.755 4.917 SGT20h3_H02
IGFBP6 9.163 6.379 SGT20n2_E09 Hs.274313
Facl4 8.656 3.001 SGT20j3_E06 Hs.81452
NGAL 8.593 10.225 SGT20n2_B01
ANXA6 8.269 4.562 SGT20p1_E11 Hs.118796
AEBP1 7.498 4.536 SGT20t5_H04 Hs.118397
GSTP1 7.319 4.592 SGT20t5_E05 Hs.226795
EFEMP2 7.254 2.088 SGT20i6_G04 Hs.381870
HGNC 6.631 2.603 SGT20i4_F11 Hs.433706
OXCT1 6.284 2.334 SGT20s4_D01 Hs.177584
SERPINF1 6.192 2.368 SGT20p2_D03 Hs.173594
ACTA2 6.170 4.074 SGT20l2_G07 Hs.195851
AEBP1 5.010 3.155 SGT20w2_B10 Hs.118397
EFEMP2 4.967 2.226 SGT20c5_E02 Hs.6059
MAN2B1 4.852 3.721 SGT20k3_F10 Hs.381666
FLJ23614 4.749 2.496 SGT20p3_C10 Hs.28780
2VIM 4.400 4.844 SGT20k1_E07 Hs.297753
FLJ20421 4.363 2.126 SGT20i3_D01 Hs.378857
FBLN1 4.113 2.024 SGT20s4_E03
FABP3 4.078 2.829 SGT20s2_D02 Hs.49881
FLNC 4.065 2.108 SGT20k1_D09 Hs.58414
RP23-38K18 on chromosome 4 3.983 2.206 SGT20h4_B11
LRP1 3.894 2.376 SGT20s4_D06 Hs.89137
CJS1 3.938 2.187 SGT20h1_E08
EPB41L1 3.502 2.668 SGT20n2_B11 Hs.253756
MGC10731 3.497 2.873 SGT20c5_B09 Hs.322487
G6PD 3.458 2.366 SGT20r1_D08 Hs.80206
EMP3 3.439 2.614 SGT20t2_E08 Hs.76884
ID2 3.424 3.370 SGT20v5_C11 Hs.9999
FTH1 3.340 2.057 SGT20j1_E06 Hs.431709
2CTSZ 3.316 2.207 SGT20h4_E12 Hs.252549
COL6A1 3.261 5.085 SGT20u4_F02 Hs.108885
HGNC 3.238 3.114 SGT20i2_H07 Hs.283611
CTSD. 3.149 3.815 SGT20q1_A04 Hs.343475Molecular Cancer 2008, 7:1 http://www.molecular-cancer.com/content/7/1/1
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sion patterns. Variations in transcriptional programs
account for much of the biological diversity of human
cells and tumors. Despite this molecular diversity, analy-
ses of invasive breast carcinomas using microarrays have
identified gene expression signatures that characterize
many of the essential qualities important for biological
and clinical classification [38]. DNA microarray profiling
studies on breast tumors show distinct and reproducible
subtypes of breast carcinoma associated with different
outcomes. Expression profiles have characterized invasive
breast carcinomas into five groups: luminal A, luminal B,
HER2+/estrogen receptor (ER)-, basal-like, and normal
breast-like. The basal-like is typically ER- and HER2- and
shows some characteristics of breast myoepithelial cells.
The basal-like subtype has been shown to have the highest
proliferation rates and poorest outcomes [39,40], and has
been described in association with BRCA-1-associated car-
cinomas [41]. Myoepithelial cells typically express cytok-
eratin 17, while luminal cells typically express
cytokeratins 8 and 18. The prevalence and poor prognosis
of basal-like breast carcinomas have been validated
immunohistochemically; in a 564-case tissue microarray,
it was demonstrated that 16% of tumors stained positive
for cytokeratin5/6 or cytokeratin 17 and that basal cytok-
eratin expression was associated with a poor prognosis
[42].
The WalBC transcript profile was compared to normal
wallaby mammary cells obtained from the same animal
and to mammary cells obtained from a virgin animal.
Microarray analysis revealed that KRT17 (30 fold up regu-
lated) was the highest up-regulated gene in the WalBC cell
line when grown as a mono-layer culture. Expression of
this gene is characteristic of basal carcinomas [42]. A 4.7
fold down regulation of VIM expression and absence of
vimentin immunoreactivity in the in situ tumor compared
to normal mammary cells suggests both the tumor and
the derived cell line have not undergone an epithelial-to-
mesenchymal transition associated with increased inva-
sive/migratory properties of epithelial cells [43,44].
WalBC cells showed regulated expression of DSP,
s100A14 and ANXA1 which are genes associated with
well-differentiated, epithelioid breast cancer cell lines
with weak invasive potential and poorly invasive tumors
[45-47]. WalBC cells also over expressed the tumor metas-
tasis suppressor NDRG1, which has been shown to be
VIP36 3.127 4.497 SGT20k3_D10 Hs.75864
P0514G12.26 3.110 2.124 SGT20n3_A08 Hs.368364
IMAGE3455200 3.031 2.166 SGT20r5_G10 Hs.425727
NPC2 2.981 2.165 SGT20e2_C10
SND1 2.934 2.001 SGT20e3_A09 Hs.79093
C4bp 2.903 2.104 SGT20i5_F10
2TIMP3 2.807 2.850 SGT20o1_A12
ZFP135 2.773 2.451 SGT20b1_F01 Hs.20848
TNC 2.772 6.720 SGT20d3_B07 Hs.289114
CRP1 2.646 2.380 SGT20l4_A03 Hs.108080
EF-1-gamma 2.615 2.379 SGT20u5_G11 Hs.256184
IQGAP3 2.611 2.136 SGT20k4_D12 Hs.78993
CPT II 2.576 2.033 SGT20s5_G03 Hs.274336
6PGD 2.495 2.522 SGT20p4_H07 Hs.392837
IGFBP2 2.421 2.249 SGT20f3_D09 Hs.433326
KIAA0627 2.417 2.164 SGT20w3_G03 Hs.108614
FKBP11 2.410 2.082 SGT20s4_F11 Hs.24048
FBLN1-D 2.392 2.902 SGT20t2_F03 Hs.79732
ZFP135 2.302 2.175 SGT20l1_H06 Hs.146854
BC012173 2.268 2.078 SGT20n4_B12 Hs.7307
ALDH7A1P1 2.214 3.149 SGT20n3_D11 Hs.76392
ALG6 2.177 2.145 SGT20d4_H03
FTL 2.156 3.180 SGT20q3_E06 Hs.433670
BC024814 2.115 2.158 SGT20h4_H07 Hs.165428
Col3A1 2.100 2.610 SGT20c4_F08 Hs.119571
SCP2 2.098 3.386 SGT20p2_H06 Hs.75760
GADD45B 2.071 4.582 SGT20k1_G01 Hs.110571
LRP1 2.042 2.326 SGT20n2_A03 Hs.251337
CD63 2.035 3.965 SGT20m3_G06 Hs.433996
dolichyl-P-Glc 2.015 2.653 SGT20m5_C11 Hs.77575
ACAT1 2.003 2.564 SGT20p4_B02
1P > 0.999 and > 2 fold
2 Previously associated with breast cancer
Table 2: Down-regulated genes in WalBC cell line. (Continued)Molecular Cancer 2008, 7:1 http://www.molecular-cancer.com/content/7/1/1
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negatively correlated with tumor metastasis. In vitro and in
vivo studies have also demonstrated a significant reduc-
tion in the metastatic ability of cells over-expressing
NDRG1[48]. The morphology of the in situ tumor also
resembled a basal-like carcinoma [49] which exhibited
solid architecture and a pushing margin.
In addition to exhibiting a gene expression profile that
correlates with poorly invasive breast cancers the WalBC
cell line also displayed a gene profile that correlated with
highly invasive cells. For example the up-regulation of
TK1 seen in WalBC cells has previously been associated
with high proliferation activity and invasiveness potential
which is related to a more aggressive phenotype [47].
Down regulation of genes such as TIMP-3 and TAGLN in
the WalBC cell line, which have been previously shown to
be associated with highly invasive breast cancer cell lines
or tumors with poor prognosis [50,51], suggests the
WalBC cell line appears to exhibit a gene expression pro-
file in common with both poorly invasive and highly
invasive cell types. WalBC also exhibited overexpression
of AQP3 which is associated with inflammatory breast
cancer [52]. Expression of these gene in the non-invasive
WalBC cell line may indicate that although these may be
markers for invasive potential expression of these genes
alone cannot invoke the invasive process.
It is clear the specific targets responsible for tumor pro-
gression need to be identified. A number of new targets
such as hypothetical proteins, CAP4, SALL1, ZONAB, and
SUMO1 were identified. These genes encoding these pro-
teins have been found to have human ortholgoues, and
with further study, may also prove to be expressed in
human cancers representing possible new molecular tar-
gets for the treatment of breast cancer. In addition, MRP8,
a newly discovered member of the ATP-binding cassette
transporter superfamily, previously identified by EST
database mining and gene prediction programming was
found to be highly expressed in human breast cancer [53]
and thus was identified as a putative molecular target for
the treatment of breast cancer. Expression of MRP8 was
also detected in the WalBC cell line and further supports
this prediction demonstrating the effectiveness the WalBC
cell line in the search for new targets of breast cancer ther-
apy and treatment. Further study of these newly identified
targets within human models of breast cancer may pro-
vide fresh clues in the development and progression of
breast cancer which may in turn lead to new treatments
and therapies.
Conclusion
Observation of analogous gene expression profiles
between human basal-like breast cancer and wallaby
breast cancer has identified a common pattern of gene
expression that appears to be characteristic for this type of
cancer regardless of species. Therefore, the use of compar-
ative oncology provides a useful tool to identify new
potential molecular targets relevant to other species. The
comparative study of breast cancer in species such as the
wallaby may provide new fundamental clues to the etiol-
ogy of breast cancer which may in turn lead to new treat-
ments and therapies. In many fields unique approaches to
drug discovery and design are being sort in order to
unearth naturally occurring factors that may be used as
potential drug therapies. One example is the use of disin-
tegrins derived from snake venom as a potential therapeu-
tic for treatment of breast cancer progression [54-56]. The
discovery of new genes identified in wallaby breast cancer
with human homologous by comparative biology may
provide useful informative for further study of aspects of
human breast cancer research, which may, in turn, lead to
new interventions and treatment regimes.
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